Results

1–10 of 11 results for Phase 2 trial

ReCLAIM-2: Phase 2 Trial of Subcutaneous Elamipretide in Patients with Noncentral Geographic Atrophy
Jeffrey S. Heier, MD
Annual Meeting Talks
2022
A Phase 2 Safety and Efficacy Trial of AU-011, a Virus-Like Drug Conjugate, With Dose Escalation and Randomized Masked Expansion in Uveal Melanoma
Prithvi Mruthyunjaya, MD, MHS
Annual Meeting Talks
2021
Ladder Phase 2 Trial of the Port Delivery System With Ranibizumab (PDS) End of Study Results
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2020
A Phase 2 Safety and Efficacy Trial of AU-011, a Virus-Like Drug Conjugate, With Dose Escalation and Randomized Masked Expansion in Uveal Melanoma
Prithvi Mruthyunjaya, MD, MHS
Updates from the Field
2021
Simultaneous Inhibition of Ang-2 and VEGF-A With Faricimab in DME: Additional Anatomical and Durability Outcomes From the BOULEVARD Phase 2 Trial
Vrinda S. Hershberger, MD, PhD
Annual Meeting Talks
2019
Suprachoroidal CLS-TA Plus Aflibercept Compared With Aflibercept Monotherapy for DME: Results of a Phase 2 Trial
Michael S. Ip, MD
Annual Meeting Talks
2019
Optimization of the Port Delivery System With Ranibizumab (PDS) Implant Insertion Procedure in the LADDER Phase 2 Trial
Mark R. Wieland, MD
Annual Meeting Talks
2019
Port Delivery System With Ranibizumab: Key Outcomes From the Ladder Phase 2 Trial That Supported Archway Phase 3 Study Design
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2019
Extended Q16W Dosing Potential for Faricimab in Neovascular Age-Related Macular Degeneration (nAMD): STAIRWAY Phase 2 Trial
Philip J. Ferrone, MD, FASRS
Annual Meeting Talks
2019
An analysis of the phase 2 trial with intraviteal aflibercept and suprachoroidal
Michael A. Singer, MD
Updates from the Field
2017